Previous Section Index Home Page

24 Oct 2005 : Column 165W—continued

Bounty Company

Tim Loughton: To ask the Secretary of State for Health what discussions her officials have had with the Bounty Company about the extension of its use in hospital for the promotion of health messages. [18737]

Mr. Byrne: Officials held discussions earlier this year with the Bounty Company to explore the possibility of distributing the Department's breastfeeding leaflet in Bounty packs. Following these discussions it was decided not to pursue this idea further.

Cancer

Bob Spink: To ask the Secretary of State for Health how many non-smokers died from lung cancer in the Essex strategic health authority in the last five years. [18777]

Ms Rosie Winterton: The information requested is not collected centrally.

Tim Loughton: To ask the Secretary of State for Health what assessment she has made of the likely effects on patients in the East Worthing and Shoreham constituency of the proposed transfer of specialist treatment of oesophagal and gastric cancer from Worthing Hospital to Brighton. [18832]

Caroline Flint: It is the responsibility of the local national health service organisations in conjunction with their cancer networks to plan and develop cancer services, and ensure that existing services comply with national guidelines published by the National Institute for Health and Clinical Excellence.
 
24 Oct 2005 : Column 166W
 

Surrey and Sussex Strategic Health Authority has advised that the proposal to transfer the service from Worthing and Southlands Hospitals NHS Trust to Brighton and Sussex University Hospitals NHS Trust was agreed by the Sussex cancer network policy board following extensive work with local NHS organisations and other stakeholders.

I understand that this proposal will enable surgery to be performed in a cancer centre with the support of a full upper gastrointestinal, oesophagal, gastric and pancreatic, cancer multi-disciplinary team.

Mr. Laurence Robertson: To ask the Secretary of State for Health what restrictions exist on (a) the advertising of cures for cancer and (b) the reporting of items relating to cancer; and if she will make a statement. [17749]

Ms Rosie Winterton: Restrictions on advertising cures of cancer are detailed in section 4(l) (a) of the 1939 Cancer Act

There are no such specific restrictions regarding the reporting of items relating to cancer.

Dr. Cable: To ask the Secretary of State for Health (1) how many people receiving cancer treatment have been sectioned under the Mental Health Act in each of the last five years for which records are available; [17782]

(2) what the known side effects relating to mental health are for each of the cancer drugs approved for use by the NHS. [17783]

Ms Rosie Winterton: Cancer treatments can cause different reactions in different people. Where side effects are experienced, they will often be short term and will subside when treatment has ended.

Psychological distress is common among people affected by cancer. In March 2004, the National Institute for Heath and Clinical Excellence produced guidance on supportive and palliative care for adults with cancer. The guidance sets out recommendations on the provision of psychological support services.

Data on the number of people detained under the Mental Health Act while receiving treatment for cancer is not available.

Dr. Cable: To ask the Secretary of State for Health how many cancer treatments have been approved by the National Institute for Health and Clinical Excellence in each of the last five years for which records are available. [17787]

Ms Rosie Winterton: To date, the National Institute for Health and Clinical Excellence (NICE) has appraised 16 cancer treatments, some for more than one type of cancer.

The table shows the cancer treatments appraised by NICE in the past five years.

Further details are available on the NICE website at: http://www.nice.org.uk.
 
24 Oct 2005 : Column 167W
 

TitlePublished
Ovarian cancer—taxanes (No. 3)—obsolete, replaced by No. 55May 2000
Breast cancer—taxanes (No. 6)—obsolete, replaced by No. 30June 2000
Brain cancer—temozolomide (No. 23)April 2001
Pancreatic cancer—gemcitabine (No. 25)May 2001
Lung cancer—docetaxel, paclitaxel, gemcitabine and vinorelbine (No. 26)—obsolete, updated by and incorporated into the guideline on the diagnosis and treatment of lung cancer (CG24)June 2001
Ovarian cancer—topotecan (No. 28)—obsolete, replaced by No. 91July 2001
Leukaemia (lymphocytic)—fludarabine (No. 29)September 2001
Breast cancer—taxanes—review (No. 30)September 2001
Breast cancer—trastuzumab (No. 34)March 2002
Colorectal cancer (advanced)—irinotecan, oxaliplatin and raltitrexed (No. 33)March 2002
Lymphoma (follicular non-Hodgkin's)—rituximab (No. 37)March 2002
Ovarian cancer (advanced)—pegylated liposomal doxorubicin hydrochloride (No. 45)—obsolete, replaced by No.91July 2002
Leukaemia (chronic myeloid)—imatinib (No. 50) obsolete, replaced by No. 70October 2002
Breast cancer—vinorelbine (No. 54)December 2002
Ovarian cancer—paclitaxel (review) (No. 55)January 2003
Breast cancer—capecitabine (No. 62)May 2003
Colorectal cancer—capecitabine and tegafur uracil (No. 61)May 2003
Non-Hodgkin's lymphoma—rituximab (No. 65)September 2003
Leukaemia (chronic myeloid)—imatinib (No. 70)October 2003
Gastro-intestinal stromal tumours (GIST)—imatinib (No. 86)October 2004
Ovarian cancer (advanced)—paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) (No. 91)May 2005
Colorectal cancer (advanced)—irinotecan, oxaliplatin and raltitrexed (review) (No. 93)August 2005

Care Homes (Diet)

Mr. Burstow: To ask the Secretary of State for Health what level of expertise and training is required of Commission for Social Care Inspection inspectors on the management of nutrition and dietary care for older people in care homes. [18939]

Mr. Byrne: I understand from the chief executive of the Commission for Social Care Inspection (CSCI), that CSCI has developed guidance for inspectors in consultation with dietary experts, on the management of nutrition and dietary care for older people in care homes.

As part of the continuous professional development for all inspectors, CSCI has established a learning resource centre, which gives inspectors access to a wide range of clinical and professional information. In addition, on a monthly basis specific care issues like the management of nutritional and dietary requirements are focused on, with electronic links provided to websites and articles providing updates on good practice.

Inspectors will prompt the provider of a care home to seek input for people in their care from local national health service dieticians, if nutritional issues are identified during an inspection.

The Chief of Nursing at CSCI has ongoing meeting with the nutritional advisory group for the elderly to discus a range of issues around nutrition.

Child Cancer Drugs

Tim Loughton: To ask the Secretary of State for Health how many children were treated for cancer with platinum based chemotherapy drugs in each of the last five years. [19025]

Ms Rosie Winterton: In the last five years there was one prescription issued for platinum based chemotherapy drugs by the national health service. Prescription information is not collected by age and therefore we cannot say if the prescription was for a child.
 
24 Oct 2005 : Column 168W
 

Child Prescriptions

Tim Loughton: To ask the Secretary of State for Health which drugs have been prescribed to children by NHS doctors in the last 12 months which have not been licensed for children. [18741]

Jane Kennedy: The Department does not collect this information.


Next Section Index Home Page